The clinical effectiveness and safety of re-induction oxaliplatin, irinotecan and fluorouracil (FOLFOXIRI regimen) for the treatment of metastatic colorectal cancer after two lines of chemotherapy (oxaliplatin- and irinotecan-based regimens)

Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer

“…A retrospective multi-center study was carried out in which eligible patients received 8-cycle modified FOLFOXIRI plus CE induction therapy every 2 weeks for up to eight cycles, as described by Cremolini et al., 8 followed by CE (intravenous 500 mg/m 2 over 60 minutes, q2w) or BE (intravenous dose of 5 mg/kg over 30 minutes, q2w) maintenance. Maintenance treatment was continued until disease progression, withdrawal, unacceptable AEs, or death for patients who were stable or better after the completion of initial induction therapy.…”

“…6 Combination treatment schedules with a modified 5-fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) regimen plus a molecularly targeted drug (cetuximab [CE] or bevacizumab [BE]) in the first-line setting have been acknowledged as the standard processing scheme on the basis of published clinical efficacy and safety profiles. [6][7][8] Previous investigators have carried out prospective Phase 1 and 2 trials to establish the safety and efficacy of modified FOLFOXIRI plus CE in the setting of KRAS and BRAF wt mCRC. 6,[9][10][11] The most recent randomized phase 2 clinical trial demonstrated that excluding patients with other RAS-mutated tumors from the KRAS and BRAF wt population may improve the benefit associated with adding CE to modified FOLFOXIRI, which is considered the best approach due to its potential to maximize the survival benefit as initial management in patients with KRAS and BRAF wt mCRC.…”